Salvianolic acid B dry powder inhaler for the treatment of idiopathic pulmonary fibrosis

• DOI: 10.1016/j.ajps.2022.04.004
• Publication Date: 2022-04-30T15:32:05Z
• Authors: Peng Lu; Jiawei Li; Chuanxin Liu; Jian Yang; Hui Peng; Zhifeng Xue; Zhidong Liu
• Keywords: Nintedanib; Dry-powder inhaler; Pirfenidone; Salvia miltiorrhiza; Ex vivo

Idiopathic pulmonary fibrosis (IPF) is a serious and fatal inflammatory disease with an increasing incidence worldwide. The drugs nintedanib pirfenidone, are listed as conditionally recommended in the "Evidence-Based Guidelines for Diagnosis Treatment of Pulmonary Fibrosis". However, these two have many adverse reactions clinical application. Salvianolic acid B (Sal B), water-soluble component Salvia miltiorrhiza, could alleviate bleomycin-induced peroxidative stress damage, prevent or delay onset IPF by regulating factors fibrotic cytokines during disease's progression. Sal poorly absorbed orally, patient compliance poor when administered intravenously. Therefore, there urgent need to find new non-injection route drug delivery. In this study, was used model l-leucine (LL) excipient prepare dry powder inhaler B-DPI) spray drying method. Modern preparation evaluation methods were assess quality B-DPI. B-DPI promising treatment IPF, according studies on irritation evaluation, vivo vitro pharmacodynamics, metabolomics, pharmacokinetics, lung tissue distribution.